Global AI in Drug Discovery Market Outlook, 2031

The global AI in drug discovery market is emerging as a transformative component of the pharmaceutical and biotechnology ecosystem, reshaping how novel therapies are identified, designed, validated, and developed. Artificial intelligence is increasingly being applied to target identification, biomarker discovery, molecular design, compound screening, toxicity prediction, drug repurposing, and clinical development, enabling researchers to analyze complex biological and chemical datasets more efficiently. The market is supported by collaboration among pharmaceutical companies, biotechnology firms, technology providers, academic institutions, research organizations, and industry associations that are promoting responsible adoption and scientific standardization. Regulatory agencies are also developing frameworks to address the opportunities and risks associated with AI-enabled drug development. The U.S. Food and Drug Administration (FDA) has issued guidance on the use of AI to support regulatory decision-making for drugs and biological products, emphasizing risk-based assessment and model credibility. The European Medicines Agency (EMA) has established principles for AI use throughout the medicinal product lifecycle and has worked with the FDA on common principles for good AI practice in drug development. Government initiatives and evolving policies concerning data governance, privacy, cybersecurity, ethical AI, and digital health are further influencing market development. Looking ahead, significant opportunities are expected through the integration of generative AI, multimodal biological data, advanced computational chemistry, real-world evidence, and AI-enabled precision medicine. Increasing regulatory convergence, standardized validation practices, responsible data-sharing frameworks, and partnerships between technology developers and life-science organizations are likely to strengthen adoption. These developments position AI-enabled drug discovery as an important avenue for improving research efficiency, accelerating innovation, and supporting the development of safer and more personalized therapies. The global AI in drug discovery market is experiencing rapid expansion as pharmaceutical and biotechnology companies increasingly integrate artificial intelligence into target identification, molecular design, virtual screening, lead optimization, and drug development workflows. The competitive landscape is highly dynamic, comprising specialized AI-native biotechnology companies, computational technology providers, established pharmaceutical organizations, and emerging startups. Key companies include NVIDIA, Schrödinger, Recursion Pharmaceuticals, Insilico Medicine, Isomorphic Labs, Atomwise, BenevolentAI, insitro, Generate Biomedicines, and Iktos. Competition is increasingly centered on the ability to combine high-quality biological datasets, advanced machine learning models, computational chemistry, automation, and experimental validation within integrated discovery platforms. Strategic partnerships between AI companies, pharmaceutical manufacturers, research institutions, and technology providers are becoming an important growth strategy, enabling companies to access proprietary datasets, expand computational capabilities, and accelerate therapeutic development. The market is also moving toward greater platform integration, with companies seeking to provide end-to-end capabilities rather than isolated AI solutions. Continued advances in generative AI, multimodal models, foundation models, automated laboratories, and precision medicine are expected to support market growth by improving research efficiency and expanding applications across therapeutic areas. As competition intensifies, companies with strong scientific expertise, proprietary data, validated AI platforms, clinical capabilities, and strategic collaborations are likely to gain stronger competitive positions. Market Dynamics Market Drivers • Increasing adoption of AI to accelerate drug discovery: Pharmaceutical and biotechnology companies are increasingly adopting AI to streamline traditionally time-consuming stages of drug discovery, including target identification, virtual screening, molecular design, lead optimization, and toxicity prediction. Continued improvements in machine learning, generative AI, computational chemistry, and biological modeling are expected to strengthen the role of AI throughout the drug discovery process. • Growing demand for cost-efficient and precision drug development: The pharmaceutical industry faces pressure to improve research productivity while reducing the resources required to discover and develop new therapies. AI offers opportunities to prioritize promising compounds, predict potential failures earlier, and optimize experimental workflows. Integration of AI with genomics, proteomics, biomarkers, and real-world data could further support personalized therapeutic discovery. Market Challenges • Data quality, availability, and integration: AI models require reliable, diverse, and well-structured datasets. Drug discovery data can be fragmented across organizations and may differ in quality, format, methodology, and completeness. Companies may need substantial investment in data management, validation, infrastructure, and interoperability before AI systems can deliver consistent results. • Regulatory, validation, and trust barriers: AI-generated predictions must be sufficiently reliable and explainable for use in highly regulated pharmaceutical research. Regulators and pharmaceutical organizations increasingly require appropriate validation and documentation of AI models. Companies must establish robust validation, governance, and risk-management frameworks, which can increase implementation complexity and slow adoption. Market Trends • Rise of generative AI and foundation models: Generative AI is becoming an important technology for designing novel molecules, predicting molecular properties, optimizing drug candidates, and exploring previously difficult biological problems. This shift could move AI from primarily supporting researchers toward becoming an active tool for generating and prioritizing new therapeutic hypotheses and drug candidates. • Expansion of AI-pharma partnerships and integrated discovery platforms: Collaboration between AI-native companies, pharmaceutical companies, biotechnology firms, academic institutions, and technology providers is becoming increasingly important. These collaborations can combine pharmaceutical expertise and proprietary datasets with advanced AI capabilities, supporting more continuous and data-driven drug discovery workflows. Segment Analysis The global AI in drug discovery market can be segmented by application into drug optimization and repurposing, preclinical testing, and others. Among these applications, drug optimization and repurposing is currently the more prevalent segment, supported by the ability of AI to analyze existing molecular, biological, clinical, and real-world datasets to identify new therapeutic uses and improve the characteristics of existing drug candidates. AI-based approaches can help researchers evaluate molecular properties, predict drug-target interactions, identify potential safety concerns, and prioritize compounds for further investigation. Drug optimization is also benefiting from generative AI and machine learning models that can propose and refine molecular structures based on desired efficacy, selectivity, pharmacokinetic, or safety characteristics. Preclinical testing represents another important application, where AI is increasingly used for toxicity prediction, pharmacokinetic assessment, disease modeling, biomarker identification, and prioritization of candidates before laboratory and clinical evaluation. A notable trend is the shift from using AI for individual analytical tasks toward integrated workflows connecting target discovery, molecule design, optimization, and preclinical evaluation. AI agents and automated laboratory systems are further supporting this transition by linking computational predictions with experimental feedback. Meanwhile, the others category includes emerging applications such as target identification, disease understanding, biomarker discovery, and AI-supported research planning. The application landscape is moving toward broader, interconnected AI platforms, with drug optimization and repurposing maintaining strong prominence while preclinical applications increasingly gain importance as companies seek to improve translation from computational predictions to experimentally validated drug candidates. The global AI in drug discovery market is segmented by therapeutic area into oncology, neurodegenerative diseases, cardiovascular disease, metabolic diseases, infectious disease, and others. Oncology is currently the most prevalent therapeutic area, reflecting the complexity of cancer biology, extensive research activity, and the growing need for targeted and personalized therapies. AI is being applied across oncology research to identify potential therapeutic targets, analyze molecular and genomic information, discover biomarkers, design compounds, and support patient stratification. Neurodegenerative diseases represent another significant area because AI can help analyze complex neurological datasets, identify disease mechanisms, discover biomarkers, and evaluate potential therapeutic candidates. Cardiovascular and metabolic diseases are also attracting increasing attention as AI platforms become capable of integrating molecular, clinical, and real-world information to support target identification and drug development. In metabolic research, growing interest in obesity and related disorders is encouraging pharmaceutical and biotechnology companies to apply AI across target discovery and molecule optimization. Infectious disease applications continue to benefit from AI-enabled molecular screening, drug repurposing, pathogen analysis, and rapid identification of potential therapeutic candidates. A key trend is the movement from disease-specific AI applications toward multimodal and precision-oriented discovery platforms that combine genomics, proteomics, imaging, clinical information, and other biological datasets. At the same time, researchers are increasingly focusing on whether AI-generated discoveries can successfully translate into clinical outcomes rather than simply demonstrating strong computational performance. Consequently, oncology remains the leading application area, while broader adoption across neurological, metabolic, cardiovascular, and infectious diseases is expanding the therapeutic scope of AI-driven drug discovery. The global AI in drug discovery market can be segmented by end use into pharmaceutical and biotechnology companies, contract research organizations (CROs), academic and research institutes, and others. Pharmaceutical and biotechnology companies represent a major and highly prevalent end-use group, as these organizations are increasingly incorporating AI into internal research pipelines and strategic partnerships to improve target identification, molecular design, drug optimization, and preclinical decision-making. AI enables companies to integrate large biological and chemical datasets and prioritize promising research opportunities while supporting more efficient discovery workflows. CROs are also becoming increasingly important because they provide specialized computational, screening, modeling, and research capabilities to organizations that may not possess extensive internal AI infrastructure. The growing use of external technology and research partnerships is encouraging CROs to develop AI-enabled services and integrated discovery solutions. Academic and research institutes contribute through fundamental research, development of new algorithms, creation of biological datasets, and collaboration with pharmaceutical and technology companies. This segment is also becoming increasingly significant as universities and research organizations participate in AI-driven drug discovery initiatives and technology transfer. A notable trend is the shift from standalone AI software toward collaborative and integrated discovery ecosystems, where pharmaceutical companies, AI developers, CROs, and academic institutions combine scientific expertise, computational capabilities, datasets, and experimental resources. Another emerging shift is toward end-to-end platforms that connect computational discovery with laboratory experimentation and clinical translation. Regional Analysis North America North America is the leading regional market for AI in drug discovery, supported by a strong pharmaceutical and biotechnology ecosystem, advanced AI capabilities, substantial research infrastructure, and close collaboration between technology companies, academic institutions, and drug developers. The U.S. is particularly prominent because of its established AI and life-sciences ecosystem and active regulatory engagement. Government and regulatory initiatives are also encouraging responsible AI adoption across the medicine lifecycle. Europe Europe represents a strong and established market for AI-enabled drug discovery, supported by its pharmaceutical industry, academic research capabilities, biotechnology clusters, and increasing investment in AI-based healthcare. Regulatory development is an important regional characteristic, with the European Medicines Agency working on guidance, tools, collaboration, and experimentation for AI across the medicine lifecycle. European institutions are also promoting access to AI computing resources and responsible AI applications in drug development. Asia Pacific Asia Pacific is emerging as one of the fastest-expanding regions for AI in drug discovery. China, Japan, India, South Korea, Singapore, and Australia are strengthening their pharmaceutical research, biotechnology, genomics, and computational capabilities. Government support is becoming particularly important; for example, China's NMPA has introduced an “AI + Drug Regulation” framework covering areas such as drug review, testing, surveillance, and regulatory infrastructure. South America South America is an emerging market for AI in drug discovery, with opportunities linked to pharmaceutical manufacturing, clinical research, healthcare datasets, and biotechnology development. Brazil is particularly relevant because of its research infrastructure and growing interest in digital health and AI applications. However, comparatively limited investment, specialized AI talent, advanced computational infrastructure, and access to high-quality datasets can constrain adoption. Continued partnerships with international pharmaceutical companies, universities, and technology providers could support regional development. Middle East and Africa The Middle East and Africa represent an early-stage but potentially promising market. Countries in the Gulf region are investing in healthcare digitization, genomics, precision medicine, and AI as part of broader technology and economic diversification strategies. Africa offers important opportunities in infectious-disease research, genomics, biobanking, and development of locally representative datasets. However, infrastructure limitations, funding constraints, data availability, and shortages of specialized expertise remain significant challenges. Key Developments • December 2025: PRISM BioLab (Japan) and Talus Bioscience (U.S.) announced a collaboration to discover novel inhibitors targeting transcription factors (TF) and protein-protein interactions (PPI). • December 2025: ChemLex, a Chinese AI-for-science startup, raised USD 45 million, led by Granite Asia, to establish its global headquarters and self-driving lab in Singapore. Signed MOU with Singapore's EDDC to accelerate small molecule discovery via automation. • October 2025: Algen Biotechnologies and AstraZeneca announced a multi-target partnership to advance AI-powered drug discovery in immunology using Algen's AlgenBrain platform. • May 2024: Every Cure and BioPhy partnered to transform drug repurposing using BioPhy’s AI platform, BioLogicAI, which identifies promising drug-disease matches and optimizes clinical trials to increase success rates and reduce costs. • March 31, 2025: Isomorphic Labs announced a USD 600 million Series A financing to expand its AI drug-design engine and advance therapeutic programs toward the clinic. • June 3, 2025: Insilico Medicine announced publication of Phase IIa rentosertib results in *Nature Medicine*, reporting a clinical proof point for an AI-discovered and AI-designed program in idiopathic pulmonary fibrosis. • January 14, 2025: Insilico Medicine announced integration of its Nach01 multimodal foundation model with Microsoft Discovery. Considered in this report • Historic Year: 2020 • Base Year: 2025 • Estimated Year: 2026 • Forecast Year: 2031 Aspects covered in this report • Global AI in Drug Discovery Market with its value and forecast along with its segments • Various drivers and challenges • Ongoing trends and developments • Top profiled companies • Strategic recommendation By Application • Drug optimization and repurposing • Preclinical testing • Others By Therapeutic Area • Oncology • Neurodegenerative Diseases • Cardiovascular Disease • Metabolic Diseases • Infectious Disease • Others By End-Use • Pharmaceutical & Biotechnology Companies • Contract Research Organizations (CROs) • Academic & Research Institutes • Others

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Ask an Expert

Sikandar Kesari

Research Analyst

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now